Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

Rhea-AI Summary

Ardelyx (ARDX) has announced its upcoming participation at TD Cowen's 45th Annual Health Care Conference. The company's management will deliver a presentation on Monday, March 3, 2025, at 9:50am ET in Boston.

The presentation will be accessible via live webcast through the Events and Presentations page on Ardelyx's investor relations website. Interested parties can view a replay of the panel presentation on the company's website for 30 days following the event.

Ardelyx is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines addressing significant unmet medical needs.

News Market Reaction – ARDX

-0.93%

1 alert

-0.93% News Effect

On the day this news was published, ARDX declined 0.93%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen’s 45^th Annual Health Care Conference on Monday, March 3, 2025 at 9:50am ET in Boston.

To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the panel presentation will be available on the Ardelyx website for 30 days following the event.

About Ardelyx, Inc.
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA^® (tenapanor) and XPHOZAH^® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL^® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com

FAQ

When is Ardelyx (ARDX) presenting at the TD Cowen Health Care Conference 2025?

Ardelyx (ARDX) is scheduled to present at TD Cowen's 45th Annual Health Care Conference on Monday, March 3, 2025, at 9:50am ET in Boston.

How can investors watch Ardelyx's (ARDX) TD Cowen conference presentation?

Investors can watch the live webcast of Ardelyx's presentation through the Events and Presentations page on the company's website at https://ir.ardelyx.com/events-and-presentations.

How long will the replay of ARDX's TD Cowen conference presentation be available?

The replay of Ardelyx's panel presentation will be available on the company's website for 30 days following the event.

What is the focus of Ardelyx's (ARDX) business according to the conference announcement?

Ardelyx is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines that meet significant unmet medical needs.